On Thursday, BofA Securities maintained their Underperform rating and an $18.00 stock price target for Myriad Genetics (NASDAQ:MYGN). Following Myriad Genetics' Analyst Day, BofA Securities commented ...

In a report released on August 7, Puneet Souda from Leerink Partners maintained a Buy rating on Myriad Genetics (MYGN – Research Report), with a price target of $35.00. Puneet Souda has given his Buy ...